PMID- 31950058
OWN - NLM
STAT- MEDLINE
DCOM- 20200702
LR  - 20220412
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2019
DP  - 2019
TI  - Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated 
      with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials.
PG  - 9283860
LID - 10.1155/2019/9283860 [doi]
LID - 9283860
AB  - BACKGROUND: Classic Hodgkin's lymphoma (cHL) is characterized by the unique 
      biology in which rare Hodgkin-Reed-Sternberg cells propagate an immunosuppressive 
      microenvironment. Checkpoint inhibitors that target the interaction of PD-1 
      immune checkpoint receptors have demonstrated remarkable activities in various 
      cancers, such as cHL. This study aims to evaluate the safety and efficacy of PD-1 
      inhibitors in treating relapsed or refractory cHL (rrHL). METHODS: We searched 
      PubMed, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, China 
      National Knowledge Infrastructure, Wanfang, Chinese Biological Medical 
      Literature, and Abstracts of Conference proceedings of annual meetings without 
      any language restrictions to limit language bias (up to January 2019) for 
      prospective clinical trials that evaluate PD-1 inhibitors in treating relapsed or 
      refractory cHL. RESULTS: A total of 9 prospective clinical trials with 731 
      patients were included in the meta-analysis. The pooled risks of all-grade and 
      grade >/=3 adverse events (AEs) were 0.86 (95% CI: 0.66-0.98) and 0.21 (95% CI: 
      0.17-0.24), respectively. The pooled response, complete response, partial 
      response, and stable disease rates were 0.74 (95% CI: 0.70-0.79), 0.24 (95% CI: 
      0.18-0.34), 0.48 (95% CI: 0.41-0.55), and 0.15 (95% CI: 0.12-0.17), respectively. 
      The pooled 6-month progression-free survival and 1-year overall survival rates 
      were 0.76 (95% CI: 0.72-0.79) and 0.93 (95% CI: 0.90-0.96), correspondingly. 
      CONCLUSIONS: Our meta-analysis suggested that anti-PD1 monoclonal antibodies 
      improve the outcomes of response and survival rates with tolerable AEs in cHL. 
      However, evidence of immune checkpoint inhibitors for patients with cHL remained 
      insufficient. Well-designed randomized controlled trials or at least 
      nonrandomized trials with a control group should be conducted to confirm the 
      findings of this meta-analysis.
CI  - Copyright (c) 2019 Xueyan Zhang et al.
FAU - Zhang, Xueyan
AU  - Zhang X
AUID- ORCID: 0000-0003-4093-0045
AD  - School of Nursing, Jilin University, Changchun, China.
FAU - Chen, Li
AU  - Chen L
AD  - School of Nursing, Jilin University, Changchun, China.
AD  - Department of Pharmacology, College of Basic Medical Sciences, Jilin University, 
      Changchun, China.
FAU - Zhao, Yawei
AU  - Zhao Y
AD  - Department of Pharmacology, College of Basic Medical Sciences, Jilin University, 
      Changchun, China.
FAU - Yin, Huiru
AU  - Yin H
AD  - School of Nursing, Jilin University, Changchun, China.
FAU - Ma, He
AU  - Ma H
AD  - Department of Anesthesiology, Second Hospital of Jilin University, Changchun, 
      Jilin, China.
FAU - He, Miao
AU  - He M
AUID- ORCID: 0000-0003-0128-348X
AD  - Department of Anesthesiology, Second Hospital of Jilin University, Changchun, 
      Jilin, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20191217
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - China/epidemiology
MH  - Clinical Trials as Topic
MH  - Drug-Related Side Effects and Adverse Reactions/classification/pathology
MH  - Hodgkin Disease/*drug therapy/genetics/immunology
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors/genetics/*immunology
MH  - Tumor Microenvironment/drug effects
PMC - PMC6948280
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/01/18 06:00
MHDA- 2020/07/03 06:00
PMCR- 2019/12/17
CRDT- 2020/01/18 06:00
PHST- 2019/08/07 00:00 [received]
PHST- 2019/11/01 00:00 [revised]
PHST- 2019/11/14 00:00 [accepted]
PHST- 2020/01/18 06:00 [entrez]
PHST- 2020/01/18 06:00 [pubmed]
PHST- 2020/07/03 06:00 [medline]
PHST- 2019/12/17 00:00 [pmc-release]
AID - 10.1155/2019/9283860 [doi]
PST - epublish
SO  - Biomed Res Int. 2019 Dec 17;2019:9283860. doi: 10.1155/2019/9283860. eCollection 
      2019.